Among other studies evaluating predictive significance of BCL-2 (Herod et al, 1996; Mano et al, 1999; Schuyer et al, 2001), including two published by Baekelandt et al, (1999,2000) on a comparable number of ovarian carcinomas, only Mano et al (1999) noticed higher frequency of CR in patients with BCL-2 negative tumours. This evidence concerns the gene BCL2 and ovarian carcinoma.